Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

Inhibitors of Bacterial DNA Synthesis

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Clinical Significance of Antibiotic Resistance

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Mechanism of Antibiotic Resistance in MRSA

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader.

Journal of medicinal chemistry·2024

Same author

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.

Journal of medicinal chemistry·2023

Same author

Novel inhibitors that target bacterial virulence identified via HTS against intra-macrophage survival of <i>Shigella flexneri</i>.

mSphere·2023

Same author

Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

Journal of medicinal chemistry·2023

Same author

Elucidation of the DNA-Binding Activity of VirF from Shigella flexneri for the <i>icsA</i> and <i>rnaG</i> Promoters and Characterization of the N-Terminal Domain To Identify Residues Crucial for Dimerization.

Journal of bacteriology·2023

Same author

Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity <i>In Vivo</i> in Acute Myeloid Leukemia.

Journal of medicinal chemistry·2023

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins

Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins

Published on: April 26, 2024

Rifamycins--obstacles and opportunities.

Paul A Aristoff¹, George A Garcia, Paul D Kirchhoff

¹Aristoff Consulting, LLC, Dexter, MI, United States.

Tuberculosis (Edinburgh, Scotland)

|March 19, 2010

Summary

Developing improved rifamycin analogs could shorten tuberculosis (TB) treatment duration and combat drug-resistant TB. Further research into these TB drugs may lead to better analogs with fewer side effects.

Area of Science:

Medicinal Chemistry
Drug Discovery
Microbiology

Background:

Tuberculosis (TB) remains a significant global health threat, causing millions of deaths annually.
Current TB treatments require lengthy durations (6-9 months) and are associated with numerous side effects.
The rise of multi-drug-resistant TB (MDR-TB) necessitates the development of novel therapeutic agents.

Purpose of the Study:

To review the current state of rifamycin analogs for TB treatment.
To explore the potential for developing improved rifamycin derivatives with enhanced efficacy and reduced toxicity.
To identify strategies for overcoming challenges associated with existing rifamycins, such as resistance and drug-drug interactions.

Main Methods:

Literature review of existing rifamycin research and development.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

High-throughput Identification of Synergistic Drug Combinations by the Overlap² Method

Published on: May 21, 2018

Related Experiment Videos

Last Updated: Jun 15, 2026

Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins

Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins

Published on: April 26, 2024

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

High-throughput Identification of Synergistic Drug Combinations by the Overlap² Method

Published on: May 21, 2018

Analysis of structure-activity relationships for rifamycin analogs.

Evaluation of in vitro and in vivo data on rifamycin efficacy and toxicity.

Discussion of potential therapeutic strategies, including higher dosing and combination therapies.

Main Results:

Rifamycins, while effective, exhibit limitations including rapid resistance development, hepatotoxicity, and significant drug-drug interactions.
Improved rifamycin analogs show potential for shorter treatment durations and activity against rifampin-resistant strains.
Certain analogs, like rifabutin and rifalazil, demonstrate reduced drug-drug interactions compared to rifampin.

Conclusions:

Development of novel rifamycin analogs is feasible and holds promise for improving TB treatment outcomes.
Further research, particularly utilizing co-crystal structures and advanced screening assays, can accelerate the discovery of superior TB drugs.
Addressing toxicity, such as the flu-like syndrome associated with some analogs, is crucial for clinical success.